Lenalidomide Stada (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the degradation of transcription factors Ikaros and Aiolos. The result is reduced tumor cell proliferation, inhibition of angiogenesis, and enhanced immune‑mediated tumor cell killing.

The specific dose of Lenalidomide Stada is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosing regimens can vary widely, and the prescriber will tailor the schedule to achieve the best therapeutic outcome while minimizing risk.

Safety data for lenalidomide in pregnancy and lactation are limited, and the drug is generally considered contraindicated for pregnant or nursing women. Women of childbearing potential should use effective contraception during treatment and for a defined period after the last dose, as advised by their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration convenience and can be combined with dexamethasone or other agents. Clinical trials have shown comparable or additive efficacy, but the choice of therapy depends on individual patient factors and prior treatment history.

Lenalidomide Stada should be stored at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not store in a refrigerator or freezer unless the label specifically indicates otherwise.

Lenalidomide Stada is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a full glass of water. Patients should follow the dosing schedule provided on the prescription label and attend regular monitoring appointments.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and an increased incidence of venous thromboembolism. Rare but critical adverse events such as secondary primary malignancies, Stevens‑Johnson syndrome, and tumor lysis syndrome also require immediate medical attention.

Patients with known hypersensitivity to lenalidomide or any component of the formulation should avoid the drug. It is also contraindicated in individuals who are pregnant, planning to become pregnant without effective contraception, or who have uncontrolled infections or severe organ dysfunction that would increase the risk of serious adverse events.